Premium
Increased expression of Fas (APO‐1, CD95) on CD34 + haematopoietic progenitor cells after allogeneic bone marrow transplantation
Author(s) -
Saheki Kaname,
Fujimori Yoshihiro,
Takemoto Yoshinobu,
Kakishita Eizo
Publication year - 2000
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2000.02022.x
Subject(s) - haematopoiesis , bone marrow , fas receptor , cd34 , immunology , progenitor cell , biology , stem cell , antigen , apoptosis , cancer research , microbiology and biotechnology , programmed cell death , biochemistry
Up‐regulation of Fas/APO‐1 (CD95) on haematopoietic progenitors and Fas‐mediated apoptosis have been suggested to occur in a possible pathological mechanism in some bone marrow failure syndromes. We examined the expression of Fas antigen and susceptibility to Fas‐mediated suppression of donor‐derived haematopoietic cells of allogeneic bone marrow transplantation (BMT) recipients. Cytofluorometric analysis revealed low expression of Fas on CD34 + bone marrow cells from marrow donors or healthy controls. However, significantly higher expression of Fas antigen was observed on CD34 + bone marrow cells of BMT recipients, in whom engraftment of donor bone marrow (BM) cells was confirmed. The addition of an agonistic anti‐Fas antibody (Ab) (CH‐11) to haematopoietic stem cell culture of BM cells more strongly suppressed colony formation from granulocyte–macrophage colony‐forming units (GM‐CFU) and erythroid burst‐forming units (BFU‐E) after BMT. Pretreatment by blocking anti‐Fas Ab (ZB4) abrogated the Fas‐mediated GM‐CFU and BFU‐E suppression. Purified marrow CD34 + cells from BMT recipients were also susceptible to the Fas‐mediated colony suppression. Thus, donor‐derived CD34 + haematopoietic cells increased their expression of Fas antigen and were susceptible to Fas‐mediated haematopoietic suppression. These findings provide new insight for understanding the haematological condition after BMT.